Skip to content
Tablet Allopathic

Exemis 25 mg tablet

Generic: Exemestane

Company: Eskayef Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength25 mg
PackStrip: 1000.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated October 29, 2025.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Exemestane 25 mg tablets

Prices as listed on BestinMeds.

2 brands listed
Exemis (this medicine)100.00 taka per tablet
Aromasin200.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Exemestane guide

Indications

Adjuvant treatment of postmenopausal women with estrogen-receptor-positive early breast cancer who have received two to three years of Tamoxifen and are switched to Exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy. Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Dosage and administration

The recommended dose of Exemestane in early and advanced breast cancer is one 25 mg tablet once daily after a meal. Adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to Exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy. The treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. Dose Modifications: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure, For patients receiving Exemestane with a strong CYP 3A4 inducer such as rifampicin or phenytoin, the recommended dose of Exemestane is 50 mg once daily after a meal

Side effects

Hot flushes Fatigue Arthralgia Headache Insomnia Increased Sweating

Precautions and warnings

Reductions in bone mineral density (BMD) over time are seen with exemestane use. Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed. Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

Pregnancy and lactation

Based on findings in animal studies and its mechanism of action, Exemestane can cause fetal harm when administered to a pregnant woman. Limited human data from case reports are insufficient to inform a drug-associated risk. In animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abortions, embryo-fetal toxicity, and prolonged gestation with abnormal or difficult labor. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. There is no information on the presence of exemestane in human milk, or on its effects on the breastfed infant or milk production. Exemestane is present in rat milk at concentrations similar to maternal plasma. Because of the potential for serious adverse reactions in breastfed infants from Exemestane, advise a woman not to breastfeed during treatment with Exemestane and for 1 month after the final dose.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250